A structure–activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1, 1′-biphenyl]-2-yl)-7-nitrobenzo [c][1, 2, 5] oxadiazol-4-amine, 1)–which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues–was executed in order to determine its pharmacophore. Whilst the 7-nitrobenzofurazan was found to be critical for inhibitory activity, the ortho-biphenyl could be replaced with a para- ...
